+447.5%
MELI vs MRNA
+554.4%
-106.9%
-69.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.5% | +5.4% | -5.8% | -0.9% |
| 7D | -4.1% | -1.1% | -3.0% | -4.0% |
| 30D | +3.8% | +126.1% | -122.3% | -9.4% |
| 3M | +17.8% | +190.0% | -172.2% | -0.8% |
| 6M | +7.4% | +157.2% | -149.8% | -8.7% |
| YTD | -5.8% | +388.2% | -394.0% | -26.7% |
| 1Y | -18.9% | +467.0% | -485.9% | -38.5% |
| 3Y | +33.3% | +36.1% | -2.7% | +15.3% |
| 5Y | +2.7% | -68.0% | +70.7% | -4.0% |
| All | +447.5% | +554.4% | -106.9% | +360.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling